People · Operator
Named in public records as an officer, director or promoter · active 2008–2015 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Audentes Therapeutics, Inc. | — | Biotechnology | Series C | $107.5M | $2.7B | 2015 |
| CymaBay Therapeutics, Inc. | — | Biotechnology | Series B | $90.6M | $12.9M | 2008 |
Louis Lange at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Louis Lange on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan Leff | 1 | 11 |
| BRADLEY BOLZON | 1 | 10 |
| Jonathan Silverstein | 1 | 10 |
| Kush Parmar | 1 | 10 |
| Thomas Woiwode | 1 | 7 |
| Anthony Evnin | 1 | 6 |
| Kurt Von Emster | 1 | 6 |
| Carl Goldfischer | 1 | 5 |
| Robert Zerbe | 1 | 5 |
| Thomas Schuetz | 1 | 4 |
| Edward E. Penhoet, Ph.D. | 1 | 3 |
| Matthew Patterson | 1 | 3 |
| Edward Penhoet | 1 | 2 |
| Donald Hill | 1 | 2 |
| Steve Squinto | 1 | 2 |
| Paul Quinlan | 1 | 1 |
| David Karpf | 1 | 1 |
| Robert J. Wills | 1 | 1 |
| Daan Van Den Noort | 1 | 1 |
| Harold Van Wart | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.